{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:06:16Z","timestamp":1787976376347,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">Helicobacter pylori (H pylori<\/jats:italic>) can cause gastritis, peptic ulcers, gastric cancer, and many other gastrointestinal diseases. The 14-day neo-dual therapy for <jats:italic toggle=\"yes\">H pylori<\/jats:italic> is considered by most countries to have good eradication rates, while the 7- and 10-day studies have been more widely explored, however, we find that their results are different. The applicability of the shorter and less expensive 10-day neo-dual therapy to our country has not yet been confirmed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The patients were divided into 3 groups of 200 each by randomization method. Group A: patients received vonoprazan 20\u2009mg, bid + amoxicillin(1\u2009g), tid, for 14 days. Group B: vonoprazan (20\u2009mg) bid + amoxicillin (1\u2009g) tid, duration of treatment is 10 days, group C: rabeprazole (20\u2009mg) bid + bismuth potassium citrate tablets\/tinidazole tablets\/clarithromycin tablets, combined package (4.2\u2009g), bid, duration of treatment 14 days. The main comparisons were <jats:italic toggle=\"yes\">H pylori<\/jats:italic> eradication rate, adverse drug reaction profile and cost\u2014effect ratio in each group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The eradication rates of groups A, B, and C were 92.5%, 91.6%, and 80.1%, respectively. There was no significant difference in the eradication rates of groups A and B (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; .05), groups A and B had statistically significantly better eradication rates than group C (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). The incidence of adverse reactions in groups A, B, and C was 9.5%, 8.5%, and 17.0%, respectively. There was no difference in the incidence of adverse reactions between A and B: (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; .05), The incidence of adverse reactions was statistically significantly lower in groups A and B than in group C (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). Logistic regression analysis showed nonsmokers had a higher eradication rate (OR 2.587, 95% CI: 1.377\u20134.859, <jats:italic toggle=\"yes\">P<\/jats:italic> = .003), and taller patients were more likely to have successful eradication (OR 1.052, 95% CI: 1.008\u20131.097, <jats:italic toggle=\"yes\">P<\/jats:italic> = .020). Group B had the lowest cost-benefit analysis results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Group B had an acceptable eradication rate, the lowest incidence of adverse effects, and the lowest cost analysis. Eradication is more likely to be successful in patients who do not smoke and in those who are taller.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035610","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:09:17Z","timestamp":1697231357000},"page":"e35610","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori"],"prefix":"10.1097","volume":"102","author":[{"given":"Faming","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Taixing Clinical College of Bengbu Medical College, Taixing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taixing Clinical College of Bengbu Medical College, Taixing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Taixing Clinical College of Bengbu Medical College, Taixing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2994-0100","authenticated-orcid":false,"given":"Xiaorong","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Taixing Clinical College of Bengbu Medical College, Taixing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.gtc.2021.02.001","article-title":"Helicobacter pylori infection.","volume":"50","author":"Cho","year":"2021","journal-title":"Gastroenterol Clin North Am"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jgh.15751","article-title":"Prevalence of Helicobacter pylori infection in China: a systematic review and meta-analysis.","volume":"37","author":"Ren","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e12637","DOI":"10.1111\/hel.12637","article-title":"Review: Helicobacter pylori and non-malignant upper gastrointestinal diseases.","volume":"24","author":"Boltin","year":"2019","journal-title":"Helicobacter"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/5584_2019_363","article-title":"Malignant helicobacter pylori-associated diseases: gastric cancer and MALT lymphoma.","volume":"1149","author":"Hatakeyama","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/j.gastro.2016.05.009","article-title":"The toronto helicobacter pylori consensus in context.","volume":"151","author":"Graham","year":"2016","journal-title":"Gastroenterology"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/florence consensus report.","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e12475","DOI":"10.1111\/hel.12475","article-title":"Fifth Chinese national consensus report on the management of Helicobacter pylori infection.","volume":"23","author":"Liu","year":"2018","journal-title":"Helicobacter"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.2147\/IDR.S358464","article-title":"Factors affect the eradication rate of Helicobacter pylori by modified quadruple therapy: a prospective cohort study.","volume":"15","author":"Lan","year":"2022","journal-title":"Infect Drug Resist"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"10838","DOI":"10.12998\/wjcc.v9.i35.10838","article-title":"Ninety-four thousand-case retrospective study on antibacterial drug resistance of Helicobacter pylori.","volume":"9","author":"Zhang","year":"2021","journal-title":"World J Clin Cases"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14656566.2017.1346087","article-title":"Vonoprazan fumarate for the management of acid-related diseases.","volume":"18","author":"Martinucci","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial.","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e12692","DOI":"10.1111\/hel.12692","article-title":"PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis.","volume":"25","author":"Gao","year":"2020","journal-title":"Helicobacter"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1128\/AAC.39.8.1859","article-title":"Bactericidal and morphological effects of amoxicillin on Helicobacter pylori.","volume":"39","author":"Berry","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.clpt.6100043","article-title":"Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.","volume":"81","author":"Furuta","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00228-008-0552-0","article-title":"Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.","volume":"65","author":"Lou","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1097\/MJT.0000000000000316","article-title":"A non-inferiority study: modified dual therapy consisting higher doses of rabeprazole is as successful as standard quadruple therapy in eradication of Helicobacter pylori.","volume":"24","author":"Sapmaz","year":"2017","journal-title":"Am J Ther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/phar.2662","article-title":"Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: an open-label, multicenter, randomized controlled trial.","volume":"42","author":"Guan","year":"2022","journal-title":"Pharmacotherapy"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/07853890.2022.2031269","article-title":"The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas.","volume":"54","author":"Shen","year":"2022","journal-title":"Ann Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1756283X16668093","article-title":"Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence.","volume":"9","author":"Akazawa","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3349\/ymj.2021.62.8.708","article-title":"Efficacy of seven-day potassium-competitive acid blocker-based first-line helicobacter pylori eradication therapy administered with bismuth.","volume":"62","author":"Kim","year":"2021","journal-title":"Yonsei Med J"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.","volume":"46","author":"Jung","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/00365521.1966.11800633","article-title":"Gastric acid secretion in patients with duodenal ulcer.","volume":"1","author":"K\u00f8ster","year":"1966","journal-title":"Scand J Gastroenterol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"e12860","DOI":"10.1111\/hel.12860","article-title":"Impact of smoking on the eradication of Helicobacter pylori.","volume":"27","author":"Yu","year":"2022","journal-title":"Helicobacter"},{"key":"R26-20250504","first-page":"gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the maastricht VI\/florence consensus report.","author":"Malfertheiner","year":"2022","journal-title":"Gut"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:15:07Z","timestamp":1746324907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":26,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035610","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}